Blood test may foretell Radiation's toll on the gut
NCT ID NCT07759258
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This observational study is investigating whether a blood marker called GLP-2 could help predict the risk and severity of acute radiation enteritis—a common and painful side effect of radiation therapy to the abdomen or pelvis. Researchers will measure GLP-2 levels in 50 adults before, at the end of, and one month after their standard radiotherapy, and track who develops gut inflammation. The goal is to see if changes in GLP-2 are linked to intestinal injury, inflammation, and quality of life, potentially paving the way for a simple blood test to guide care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Abdominopelvic radiotherapy (standard of care, not modified by the study)
- What this could lead to
- If GLP-2 levels correlate with radiation enteritis, it could become a simple blood test to identify patients at higher risk, enabling earlier intervention or treatment adjustments.
- What could go wrong
- This is a small observational study, so it can only show associations, not cause and effect. The results may not apply to all patients or lead to a proven clinical test.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will consist of approximately 50 adults aged 18 to 75 years with malignant tumors who are scheduled to receive abdominopelvic radiotherapy at a single medical center. Eligible participants will be enrolled prospectively before radiotherapy and followed throughout radiotherapy until 1 month after treatment completion. Participants will receive routine clinical care without any study-assigned therapeutic intervention. Residual blood samples from routine clinical testing and relevant clinical, symptom, nutritional, radiotherapy, and quality-of-life data will be collected.
- Ages
-
18 to 75 years
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Inclusion Criteria: 1. Age 18 to 75 years. 2. Diagnosed with a malignancy and scheduled to receive abdominopelvic radiotherapy. 3. No active enteritis or moderate-to-severe diarrhea before radiotherapy. 4. Expected to complete the planned course of radiotherapy and the 1-month post-radiotherapy follow-up. 5. Able to complete clinical data collection, gastrointestinal symptom assessment, nutritional assessment, quality-of-life assessment, and collection of residual peripheral venous blood samples from routine clinical testing. 6. Willing to participate and able to provide written informed consent. Exclusion Criteria: 1. Moderate-to-severe diarrhea, active inflammatory bowel disease, intestinal obstruction, short bowel syndrome, or severe malabsorption before radiotherapy. 2. Previous radiotherapy to the same abdominopelvic region. 3. Severe cardiac, hepatic, or renal failure. 4. Active infection, severe systemic inflammatory response, or active autoimmune disease. 5. Receipt during the study of treatments considered by the investigator to substantially affect intestinal hormones, inflammatory markers, or intestinal barrier function and interfere with the study results. 6. Pregnancy or breastfeeding. 7. Any other condition that, in the investigator's judgment, makes the individual unsuitable for participation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Malignancy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune checkpoint drugs fight cancers beyond their approved uses?
- Bacterial wall chemical injected into tumors shows promise in early safety trial
- New radiation method aims to shrink large tumors
- Which sedation works best for bile duct procedures? new study aims to find out
- Zapping just a few spots: new hope for patients with worsening metastatic cancer?
- Massive UK study tracks cancer after organ transplants